Upstream Bio FY2025 net loss widens 128.4% to $143 million; research and development expenses rise 117.3% to $137 million

Reuters

Mar 26

Upstream Bio FY2025 net loss widens 128.4% to $143 million; research and development expenses rise 117.3% to $137 million

Upstream Bio published a press release reporting fourth-quarter and full-year 2025 financial results and outlining its Phase 3 development strategy for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps.
Cash, cash equivalents and short-term investments totaled USD 341.5 million as of Dec. 31, 2025, with the company expecting this to fund planned operations through 2027.
Research and development expenses rose 84.46% to USD 40.2 million for the quarter, driven primarily by higher clinical and manufacturing expenses for verekitug programs.
Net loss widened 99.86% to USD 42.5 million for the quarter.
Management said it plans to initiate dosing in Phase 3 trials for verekitug in severe asthma and CRSwNP in Q1 2027, following positive Phase 2 results and planned FDA engagement later this year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260700PRIMZONEFULLFEED9678996) on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2622851551"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622851551\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622851551?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622851551","market":"nz","top_or_hot":-1,"title":"Upstream Bio FY2025 net loss widens 128.4% to $143 million; research and development expenses rise 117.3% to $137 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Upstream Bio FY2025 net loss widens 128.4% to $143 million; research and development expenses rise 117.3% to $137 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Upstream Bio published a press release reporting fourth-quarter and full-year 2025 financial results and outlining its Phase 3 development strategy for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps.\n        </li>\n<li>\n          Cash, cash equivalents and short-term investments totaled USD 341.5 million as of Dec. 31, 2025, with the company expecting this to fund planned operations through 2027.\n        </li>\n<li>\n          Research and development expenses rose 84.46% to USD 40.2 million for the quarter, driven primarily by higher clinical and manufacturing expenses for verekitug programs.\n        </li>\n<li>\n          Net loss widened 99.86% to USD 42.5 million for the quarter.\n        </li>\n<li>\n          Management said it plans to initiate dosing in Phase 3 trials for verekitug in severe asthma and CRSwNP in Q1 2027, following positive Phase 2 results and planned FDA engagement later this year.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260700PRIMZONEFULLFEED9678996) on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Upstream Bio FY2025 net loss widens 128.4% to $143 million; research and development expenses rise 117.3% to $137 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpstream Bio FY2025 net loss widens 128.4% to $143 million; research and development expenses rise 117.3% to $137 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Upstream Bio FY2025 net loss widens 128.4% to $143 million; research and development expenses rise 117.3% to $137 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Upstream Bio published a press release reporting fourth-quarter and full-year 2025 financial results and outlining its Phase 3 development strategy for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps.\n        </li>\n<li>\n          Cash, cash equivalents and short-term investments totaled USD 341.5 million as of Dec. 31, 2025, with the company expecting this to fund planned operations through 2027.\n        </li>\n<li>\n          Research and development expenses rose 84.46% to USD 40.2 million for the quarter, driven primarily by higher clinical and manufacturing expenses for verekitug programs.\n        </li>\n<li>\n          Net loss widened 99.86% to USD 42.5 million for the quarter.\n        </li>\n<li>\n          Management said it plans to initiate dosing in Phase 3 trials for verekitug in severe asthma and CRSwNP in Q1 2027, following positive Phase 2 results and planned FDA engagement later this year.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260700PRIMZONEFULLFEED9678996) on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL8rp4hV:1","article_id":"2622851551","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622851551","pubTimestamp":1774522954,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Upstream Bio published a press release reporting fourth-quarter and full-year 2025 financial results and outlining its Phase 3 development strategy for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps.Cash, cash equivalents and short-term investments totaled USD 341.5 million as of Dec. 31, 2025, with the company expecting this to fund planned operations through 2027.Research and development expenses rose 84.46% to USD 40.2 million for the quarter, driven primarily by higher clinical and manufacturing expenses for verekitug programs.Net loss widened 99.86% to USD 42.5 million for the quarter.Management said it plans to initiate dosing in Phase 3 trials for verekitug in severe asthma and CRSwNP in Q1 2027, following positive Phase 2 results and planned FDA engagement later this year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4112":"金融交易所和数据","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","UPB":"UpStream Bio Inc."},"translate_title":"Upstream Bio 2025财年净亏损扩大128.4%至1.43亿美元；研发费用增长117.3%至1.37亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UPB":0.9,"NDAQ":0.9},"content_text":"Upstream Bio FY2025 net loss widens 128.4% to $143 million; research and development expenses rise 117.3% to $137 million\n    \n\n\n          Upstream Bio published a press release reporting fourth-quarter and full-year 2025 financial results and outlining its Phase 3 development strategy for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps.\n        \n\n          Cash, cash equivalents and short-term investments totaled USD 341.5 million as of Dec. 31, 2025, with the company expecting this to fund planned operations through 2027.\n        \n\n          Research and development expenses rose 84.46% to USD 40.2 million for the quarter, driven primarily by higher clinical and manufacturing expenses for verekitug programs.\n        \n\n          Net loss widened 99.86% to USD 42.5 million for the quarter.\n        \n\n          Management said it plans to initiate dosing in Phase 3 trials for verekitug in severe asthma and CRSwNP in Q1 2027, following positive Phase 2 results and planned FDA engagement later this year.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260700PRIMZONEFULLFEED9678996) on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}